Monthly Archives: September 2013

'Immunotherapy in Alzheimer's disease' – special series call for submissions

Alzheimer’s Research & Therapy is accepting research submissions for consideration in a special series on immunotherapy in Alzheimer’s disease. Accumulation of amyloid-beta protein (Aβ) and hyperphosphorylated tau protein are the pathological hallmarks of Alzheimer’s disease (AD), the most common form of dementia. The current approved therapies for AD consist of symptomatic treatments, which do not… Read more »

Cochrane Methodology Anniversary Series

CC20-logo-horizontal-rgb-small

Posted on behalf of Professor Mike Clarke, Director, All Ireland Hub for Trials Methodology Research, Queen’s University Belfast and Co-ordinating Editor, Cochrane Methodology Review Group It’s not quite a case of ‘it was 20 years ago today’, but 2013 sees the 20th anniversary of the establishment of The Cochrane Collaboration, the world’s largest organisation producing systematic… Read more »

New antibiotics for bad bugs

Hospital-associated MRSA

Increasing bacterial resistance to antibiotics is becoming a critical problem worldwide. The European Union have set out a ‘roadmap against antibiotic resistance’ to tackle the issue in Europe. In the UK, England’s Chief Medical Officer has suggested the threat of antibiotic resistance is ‘arguably as important as climate change for the world’. A new review… Read more »

Alzheimer’s disease: would you want to know?

If there were an early medical test for Alzheimer’s disease (AD), would you choose to take it? Most adults would, suggests a study in the open access journal Alzheimer’s Research & Therapy. The potential repercussions of this could be high, with medical, political and legal ramifications. Alzheimer’s disease is the most common type of dementia,… Read more »